Cannabidiol - A new fixture in childhood neurology

Christopher L Anderson; Paul R Carney

doi:10.1016/j.coph.2021.10.002

Cannabidiol - A new fixture in childhood neurology

Curr Opin Pharmacol. 2021 Dec:61:142-146. doi: 10.1016/j.coph.2021.10.002. Epub 2021 Nov 19.

Authors

Christopher L Anderson¹, Paul R Carney²

Affiliations

¹ Department of Child Health, University of Missouri, Columbia, MO 65201, USA.
² Department of Child Health, University of Missouri, Columbia, MO 65201, USA; Department of Biomedical, Biological and Chemical Engineering, University of Missouri, Columbia, MO 65201, USA. Electronic address: prcarney@health.missouri.edu.

PMID: 34808574
DOI: 10.1016/j.coph.2021.10.002

Abstract

This invited opinion article reviews current uses and controversies in vernacular and pharmacological cannabidiol use in pediatric neurologic disorders. Since the recent emergence of cannabidiol availability to the general public and recent Food and Drug Administration approval, it is important to highlight and expand understanding about CBD mechanism of action, long-term use, safety, and indications in children with neurological disorders.

Keywords: Autism; Behavior; Cannabidiol; Epilepsy; Microbiome; Sleep.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Review

MeSH terms

Anticonvulsants / therapeutic use
Cannabidiol* / therapeutic use
Child
Humans
Nervous System Diseases* / drug therapy
Neurology*

Substances

Anticonvulsants
Cannabidiol

Abstract

Publication types

MeSH terms

Substances

Grants and funding